Does the method of treatment of acutely ruptured intracranial aneurysms influence the incidence and duration of cerebral vasospasm and clinical outcome?

A J P Goddard, P P J Raju, A Gholkar

Cerebral vasospasm causes permanent neurological deficit in 40–70% survivors of subarachnoid haemorrhage (SAH). Vasospasm is a potentially treatable condition and the earlier the treatment the better the outcome. Ventilated patients or patients in otherwise poor neurological condition are not assessable in the standard manner, and unrecognised and untreated spasm may be devastating.

Oxyhaemoglobin and other erythrocyte breakdown products secondary to SAH are reported to be spasmogenic. Early cisternal cerebrospinal fluid (CSF) washout to remove blood is performed during the operative repair of aneurysms and has been shown to reduce the incidence of cerebral vasospasm and hydrocephalus. Endovascular treatment has the theoretical disadvantage that CSF irrigation cannot be performed, potentially increasing the risk of vasospasm.

Transcranial Doppler (TCD) analysis has been used for many years to assess intracranial blood flow and has been demonstrated to have a positive impact on patient management. It is routinely used in our centre to monitor for changes in cerebral blood flow that herald the onset of vasospasm and to direct and monitor subsequent management—for example, during nimodipine treatment and after vasospasm and to direct and monitor subsequent management changes in cerebral blood flow that herald the onset of vasospasm and hydrocephalus. Endovascular treatment and has been shown to reduce the incidence of cerebral vasospasm and its clinical consequences.

Methods: Admission data, cranial computed tomography (CT), treatment details, transcranial Doppler (TCD) results, and clinical outcomes of patients who had surgical or endovascular management of their ruptured aneurysm were recorded and subject to multivariate analysis.

Results: Between January 1995 and December 1999, 292 eligible patients (206 female, 86 male) had definitive aneurysm treatment at our unit. 212 patients were clipped, 80 coiled. There was no significant difference in patient age, pre-treatment neurological grade, Fisher grade, or timing of treatment in the two groups. 48.3% patients developed TCD detected cerebral vasospasm and 16.1% patients developed permanent ischaemic neurological deficit. At clinical follow up, 84.2% of patients were well (mGOS 1 and 2) with a cumulative death rate of 6.5% from all causes. The only significant predictor of TCD-detected cerebral vasospasm was patient age (inversely, \( p = 0.004 \)). Increased patient age, vasospasm, poor pre-treatment WFNS, and higher CT Fisher grades correlated with a poor discharge GOS. However, only poor pre-treatment WFNS grade and patient age correlated with poor GOS at follow up (\( p < 0.001 \)).

Conclusion: The treatment method had no influence on the incidence or duration of TCD detected vasospasm and there was no significant difference in outcome at discharge or follow up between those patients who had surgery or endovascular management of their aneurysms.

Materials and methods

The case notes, TCD results, cranial computed tomography (CT) examinations, angiograms, and outpatient correspondence were reviewed for all patients who received definitive treatment for ruptured aneurysms from January 1995 to December 1999. During this time a single operator was performing Guglielmi Detachable Coils (GDC) embolisation, an experienced team of neurosurgeons operated on our patient cohort, and a single operator performed TCD analysis. All patients underwent cranial CT to confirm a clinical diagnosis of SAH. If CT was normal, all patients underwent lumbar puncture to detect CSF xanthochromia unless there was a contraindication. Only patients with unequivocally positive results were included in the analysis. All patients had four-vessel cerebral angiography performed prior to planning treatment.

The method of aneurysm treatment was made on an individual patient basis, depending on clinical grade, aneurysm location and morphology, and co-morbidity. Where appropriate, treatment was randomised as part of the International Subarachnoid Aneurysm Trial (ISAT). All patients were admitted either to intensive care or the high dependency unit for a minimum of 24 hours after the procedure and received equivalent levels of care appropriate to their condition. Oral or intravenous nimodipine was administered to all patients for a minimum of 21 days depending on clinical condition.

Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; GDC, Guglielmi Detachable coils; ISAT, International Subarachnoid Aneurysm Trial; mGOS, modified Glasgow Outcome Score; SAH, subarachnoid haemorrhage; TCD, transcranial Doppler
TCD monitoring with a 2 MHz probe commenced at day one and continued on alternate days until death, clinical recovery, or normalisation of velocities. Bilateral pterional insonation was performed on the intracranial internal carotid A1 and M1 vessels. Suboccipital insonation was performed to measure velocities in the basilar artery. Patients were excluded from the analysis if TCD was unable to be performed—for example, absence of an acoustic window—or an incomplete study only was possible.

The presence of vasospasm was defined as a rise above 120 cm/s in any insonated vessel. This low velocity threshold increases sensitivity and allows preventative treatment to be given. Development of focal neurological deficit or deterioration in conscious level was noted. In the setting of neurological deterioration, cranial CT was performed to exclude non-ischaemic causes—for example, post-operative haematoma, re-bleed, and hydrocephalus. Patients having a non-ischaemic cause for their deterioration continued to be monitored and only a deficit directly attributable to ischaemia was recorded.

Standard haemodilution, hypertension, and hyperhydration (triple-H) treatment was given if the patient showed TCD or clinical signs of cerebral vasospasm. This was continued along with other medical treatments as appropriate until the patient recovered, died, or TCD velocities normalised. If the patient continued to deteriorate despite intensive triple-H treatment, then consideration was given to performing papaverine infusion directly into the affected vessels.

Specific complications related to treatment or significant systemic complications of SAH were noted.

Mortality and modified Glasgow Outcome Score (mGOS) were recorded for all patients at discharge and follow up 4–8 months post-treatment. Patients were excluded from analysis if there was incomplete follow up data.

RESULTS
Pre-treatment patient characteristics
A total of 292 patients satisfied the selection criteria for analysis. Age, sex, pre-treatment World Federation of Neurological Surgeons (WFNS) grade, CT Fisher grade, aneurysm location, time between haemorrhage and treatment, presence of vasospasm, ischaemic neurological deficit, discharge, and follow up mGOS were recorded and these data are presented in table 1. Additional data recorded included duration of vasospasm and specific complications. Statistical analysis was performed with commercial software (SPSS for Windows, Release 7.7.1).

Mantel-Haenszel $\chi^2$ analysis for differences in trends showed significantly higher CT Fisher grade patients receiving endovascular treatment ($p = 0.044$). There was a non-significant predominance of posterior circulation aneurysms and poorer grade patients in the endovascular group ($p = 0.18$). There was no significant difference in patient age or sex in the two groups.

A total of 220 aneurysms were clipped in 212 patients and 80 aneurysms in 80 patients were coiled. Seven patients had two aneurysms clipped at one sitting; one patient had a second aneurysm clipped 2 days after the first. In these cases, there was doubt as to which aneurysm had ruptured. One patient had an anterior choroidal aneurysm coiled then subsequently clipped, one had an anterior communicating artery aneurysm clipped and wrapped, and one had a small carotid-ophtalmic aneurysm wrapped.

Incidence of TCD detected cerebral vasospasm
Thirty eight out of 80 (47.5%) of coiled and 103/212 (48.6%) of clipped patients (141/292 [48.3%] overall) developed TCD velocities above 120 cm/s. The characteristics of those patients who did and did not develop TCD vasospasm and those who developed ischaemic neurological deficit are shown in table 1. Pearson $\chi^2$ and Mantel-Haenszel $\chi^2$ analysis of the following variables showed no correlation with the incidence of vasospasm: method of treatment ($p = 0.696$), patient sex ($p = 0.923$), aneurysm site ($p = 0.892$), WFNS grade ($p = 0.496$), and CT Fisher grade ($p = 0.932$).

Multiple logistic regression analysis confirmed that the only independent factor correlating with the presence of TCD detected vasospasm was young patient age ($p = 0.0037$).

Ninety one (64.5%) patients had treatment prior to onset of vasospasm, 32 (22.7%) had treatment after vasospasm onset, and 18 (12.8%) had treatment on the same day spasm was demonstrated. There was no difference in treatment method in these groups. Two patients underwent papaverine infusion to allow endovascular aneurysm treatment. Four patients had papaverine infusion after their aneurysms had been clipped. All of these patients showed significant TCD velocity rises, indicating good correlation between TCD findings and angiography in this group.

There was no significant difference in the proportion of patients in either treatment group who suffered ischaemic neurological deficit (Pearson $\chi^2$: $p = 0.69$) or in the groups of patients who had TCD velocity rises ($p = 0.089$).

There was no difference in the duration of vasospasm in two groups (Mann-Whitney U test; $p = 0.975$). Mean spasm duration was 2.9 days (95% confidence interval [CI]: 1.3 to 4.5) and 2.88 days (95% CI: 2.08 to 3.68) in patients with and without delayed ischaemic neurologic deficit (DIND), respectively.

Patient outcomes
Nineteen out of 292 (6.5%) patients died in hospital: 18/19 (95%) as a direct result of SAH or treatment and one died due to systemic complications. Eight out of 19 (42%) patients developed TCD velocities indicative of vasospasm; not significantly different from our overall patient population.

Table 1 documents the mGOS of the patients at the time of discharge and follow up. A total of 221/292 (75.7%) patients were well (mGOS I and II) at discharge, which increased to 246/292 (84%) at follow up. The capacity for recovery was directly related to discharge mGOS: 66% of mGOS II, 74% of mGOS III, and 40% of mGOS IV patients improved at follow up. There was no difference in functional recovery between coiled and clipped patients who developed TCD velocity rises and neurological deficit.

Seven patients died during the follow up period: five succumbed to complications of their haemorrhage and two died of unrelated causes. Multivariate analysis of factors influencing outcome at discharge and follow up is summarised in table 2.

Six patients re-bleed prior to surgical (four patients) or endovascular (two patients) treatment. Five out of six patients (83%) developed vasospasm and two of these patients died. Two patients were vegetative (mGOS 4) and two were mGOS 2. Eight patients suffered intra-procedural aneurysm rupture (six surgical, two endovascular). Three of these patients died soon after and three of the remaining five patients (60%) developed vasospasm and were mGOS 1, 2, and 3 at follow up. The two patients who did not develop vasospasm were mGOS 2 and 3 at follow up. One patient died because of early re-rupture after coiling of an anterior communicating artery aneurysm. Preprocedure and periprocedure re-rupture were significant predictors of a poor outcome in both groups with a mortality and major morbidity (mGOS 4 and 5) of 50% and were responsible for five out of 19 (26%) of all deaths ($p < 0.001$).
Cerebral vasospasm is a significant determinant of patient outcome even after technically successful aneurysm treatment. Vasospasm affects between 30% and 70% of patients and leads to clinically significant neurological deficit in 30% of survivors. The aetiology of this phenomenon has been much studied but remains only partially understood. It would seem that both subarachnoid blood and manipulation of the brain and vessels could lead to vasospasm.

The incidence of symptomatic vasospasm after endovascular treatment of aneurysms has been reported between 19% and 23%. This compares well with surgical series. Our clinical results also correlate with these series with ischaemic neurological deficit occurring in 13.8% of endovascular and 16.5% of surgical patients.

### Table 1 Patient demographics

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Overall</th>
<th>Surgical</th>
<th>Endovascular</th>
<th>TCD vasospasm</th>
<th>No spasm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range</td>
<td>18–84</td>
<td>18–84</td>
<td>18–84</td>
<td>19–82</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>53.7</td>
<td>53.7</td>
<td>54.0</td>
<td>53.6</td>
<td>53.8</td>
</tr>
<tr>
<td>95% CI</td>
<td>52.1–55.3</td>
<td>51.8–55.6</td>
<td>50.9–57.1</td>
<td>51.3–56.0</td>
<td>51.5–56.1</td>
</tr>
<tr>
<td>Sex</td>
<td>M (%)</td>
<td>85</td>
<td>64 (31.1)</td>
<td>21 (26.3)</td>
<td>41/141 (29.1)</td>
</tr>
<tr>
<td></td>
<td>F (%)</td>
<td>203</td>
<td>144 (68.9)</td>
<td>59 (73.7)</td>
<td>100/141 (70.9)</td>
</tr>
<tr>
<td>Aneurysm location</td>
<td></td>
<td>A com</td>
<td>107 (35.7)</td>
<td>74 (33.6)</td>
<td>33 (41.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P com</td>
<td>83 (27.7)</td>
<td>59 (26.8)</td>
<td>24 (30)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MCA</td>
<td>66 (22)</td>
<td>58 (26.4)</td>
<td>8 (10)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Car oph</td>
<td>6 (2)</td>
<td>4 (1.8)</td>
<td>2 (2.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICA oth</td>
<td>19 (6.3)</td>
<td>13 (5.9)</td>
<td>6 (7.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pericallosal</td>
<td>7 (2.3)</td>
<td>7 (3.2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post car A</td>
<td>2 (0.7)</td>
<td>1 (0.45)</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PICA</td>
<td>4 (1.3)</td>
<td>1 (0.45)</td>
<td>3 (3.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BA</td>
<td>6 (2)</td>
<td>3 (1.4)</td>
<td>3 (3.7)</td>
</tr>
<tr>
<td>Fisher grade</td>
<td></td>
<td>I</td>
<td>33 (11.4)</td>
<td>28 (13.4)</td>
<td>5.6 (2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>91 (31.5)</td>
<td>69 (33)</td>
<td>22 (27.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>87 (30.1)</td>
<td>64 (30.6)</td>
<td>23 (28.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV</td>
<td>78 (27)</td>
<td>48 (23)</td>
<td>30 (37.5)</td>
</tr>
<tr>
<td>WFNS grade</td>
<td></td>
<td>I</td>
<td>126 (43.6)</td>
<td>96 (45.9)</td>
<td>30 (37.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>69 (23.9)</td>
<td>50 (24)</td>
<td>19 (23.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>50 (17.3)</td>
<td>37 (17.7)</td>
<td>13 (16.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV</td>
<td>38 (13.1)</td>
<td>23 (11.0)</td>
<td>15 (18.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V</td>
<td>6 (2.1)</td>
<td>3 (1.4)</td>
<td>3 (3.7)</td>
</tr>
<tr>
<td>Time between ictus and Rx (days)</td>
<td></td>
<td>Range</td>
<td>0–52</td>
<td>0–52</td>
<td>0–33</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mean</td>
<td>5.45</td>
<td>5.46</td>
<td>5.54</td>
</tr>
<tr>
<td></td>
<td></td>
<td>95% CI</td>
<td>4.7–6.2</td>
<td>4.5–6.4</td>
<td>4.0–7.1</td>
</tr>
<tr>
<td>Ischaemic neurological deficit</td>
<td></td>
<td>Yes</td>
<td>47/292 (16.1)</td>
<td>35/212 (16.5)</td>
<td>11/80 (13.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No</td>
<td>245/292 (83.9)</td>
<td>177/121 (83.5)</td>
<td>69/80 (86.2)</td>
</tr>
<tr>
<td>Modified GOS discharge</td>
<td></td>
<td>I</td>
<td>114 (39.1)</td>
<td>82 (38.7)</td>
<td>32 (40)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>107 (36.6)</td>
<td>85 (40.1)</td>
<td>22 (27.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>37 (12.7)</td>
<td>23 (10.8)</td>
<td>14 (17.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV</td>
<td>15 (5.1)</td>
<td>9 (4.3)</td>
<td>6 (7.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V</td>
<td>19 (6.5)</td>
<td>13 (6.1)</td>
<td>6 (7.5)</td>
</tr>
<tr>
<td>Follow up</td>
<td></td>
<td>I</td>
<td>187 (64)</td>
<td>134 (63.2)</td>
<td>53 (66.25)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>59 (20.2)</td>
<td>50 (23.6)</td>
<td>9 (11.25)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>13 (4.5)</td>
<td>7 (3.3)</td>
<td>6 (7.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV</td>
<td>7 (2.4)</td>
<td>4 (1.9)</td>
<td>3 (3.75)</td>
</tr>
<tr>
<td>TCD velocity</td>
<td>&gt;120 cm/s</td>
<td>26 (8.9)</td>
<td>17 (8.9)</td>
<td>11 (25)</td>
<td></td>
</tr>
</tbody>
</table>

TCD, transcranial Doppler; CI, confidence interval; A com, anterior communicating artery; P com, posterior communicating artery; MCA, middle cerebral artery; Car oph, carotid ophthalmic; ICA, internal carotid artery; PICA, posterior inferior cerebellar artery; BA, basilar artery; WFNS, World Federation of Neurological Surgeons; Rx, treatments; GOS, Glasgow Outcome Score.

### Table 2 Multivariate analysis of the correlation between clinical and treatment parameters and patient outcome at discharge and follow up

<table>
<thead>
<tr>
<th>Discharge GOS</th>
<th>Outpatient GOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>NS (p = 0.001)</td>
</tr>
<tr>
<td>Sex</td>
<td>S (p = 0.001)</td>
</tr>
<tr>
<td>Aneurysm site</td>
<td>NS (p = 0.089)</td>
</tr>
<tr>
<td>Treatment</td>
<td>NS (p = 0.160)</td>
</tr>
<tr>
<td>Timing of treatment</td>
<td>NS (p = 0.128)</td>
</tr>
<tr>
<td>Fisher grade</td>
<td>S (p = 0.0014)</td>
</tr>
<tr>
<td>WFNS grade</td>
<td>S (p = 0.001)</td>
</tr>
<tr>
<td>TCD velocity</td>
<td>S (p = 0.012)</td>
</tr>
</tbody>
</table>

GOS, Glasgow Outcome Score; NS, not significant; S, significant; TCD, transcranial Doppler.

### DISCUSSION

Cerebral vasospasm is a significant determinant of patient outcome even after technically successful aneurysm treatment. Vasospasm affects between 30% and 70% of patients and leads to clinically significant neurological deficit in 30% of survivors. The aetiology of this phenomenon has been much studied but remains only partially understood. It would seem that both subarachnoid blood and manipulation of the brain and vessels could lead to vasospasm.

The incidence of symptomatic vasospasm after endovascular treatment of aneurysms has been reported between 19% and 23%. This compares well with surgical series. Our clinical results also correlate with these series with ischaemic neurological deficit occurring in 13.8% of endovascular and 16.5% of surgical patients.

Yalamanchilli et al. in 37 patients (19 clipped, 18 coiled) demonstrated significant reduction in spasm in the
endovascular group compared with surgery. The reasons are likely to be multifactorial, but vessel manipulation, diuresis, and release of blood and prostaglandins as a result of surgery probably outweigh any potential benefit of CSF washout and irrigation with thrombolytic or papaverine.

The largest study into the effects of aneurysm treatment on the incidence of vasospasm was reported by Charpentier et al. in 244 patients. Their retrospective data included more endovascular cases (145 v 99 surgical) but reached similar conclusions; there is no significant difference in the incidence of cerebral vasospasm in surgical (22.2%) or endovascular (17.2%) groups, and young age and treatment complications were a significant predictor of vasospasm occurrence. They also showed a significant correlation between good neurological grade and occurrence of vasospasm, although we demonstrated no such association.

Their study also focused on the important impact of secondary brain insults, such as hyperglycaemia in exacerbating neurological damage. Pre-existing medical conditions and secondary insults undoubtedly contribute in individual cases and explain the poorer outcomes in the elderly across all clinical grades.

The sensitivity of TCD for the detection of cerebral vasospasm in the anterior cerebral circulation ranges from 53% in the anterior communicating artery to 93% in the middle cerebral artery with specificity up to 100% in the anterior and middle cerebral arteries. TCD of the posterior circulation yields a sensitivity and specificity of 44.0% and 87.5% for vertebral and 76.9% and 79.3% for basilar artery vasospasm, although its use here is less widespread.

A velocity reading of 120 cm/s may be regarded as a significant rise and a predictor of the presence of angiographic vasospasm. However, several studies, including our own, have been unable to establish a direct correlation between absolute TCD velocities and the onset of ischaemic neurological deficit. There are technical and physiological reasons why this may be so. A rise in TCD velocities may not indicate vasospasm in the setting of impaired cerebral autoregulation when increases in circulating volume and hypertension (induced by triple-H treatment) increase cerebral blood flow sufficiently to be detected as a TCD velocity rise. The expected velocity increases due to vasospasm may be dampened in the setting of raised intracranial pressure. This is particularly so when mean velocities are measured. Patients with systemic hypertension may not demonstrate the rise in TCD velocities expected with the onset of vasospasm. Insolated vessels may demonstrate normal velocity if flow is dampened by proximal focal spasm. Additionally, complex flow patterns in patients with SAH-related neurological deterioration have been demonstrated on positron emission tomography suggesting combined hyperperfusion and vasospasm in some cases, which would clearly cause misleading TCD results.

Although TCD is sensitive to spasm in proximal vessels, vasospasm affects distal vessels also and TCD results may not reflect the severity of spasm in these territories and therefore may not predict clinical outcome. Another possible explanation for the lack of clinical correlation between high TCD velocities and neurological deficit is that the institution of therapeutic measures in response to such TCD velocity rises (particularly triple-H treatment) is effective in averting DIND. Our data do not allow us to test these hypotheses, but it is likely to be a combination of factors.

TCD detected proximal vessel velocity increase is only part of the physiological and clinical profile of the condition of cerebral vasospasm and ischaemia. Defining cerebral vasospasm by relatively low velocity measurements may include patients who do not have vasospasm at all. However, the distribution of false positive results is not expected to be different between the two treatment groups and would not be expected to affect the validity of our findings. High TCD velocities associated with neurological deficit clearly indicate vasospasm, but the opportunity to institute effective treatment may have passed if one accepts these more specific criteria for diagnosis.

Discharge mGOS was directly related to the effects of the initial haemorrhage, patient age, and the presence of high TCD velocities. There was no correlation with the treatment method.

Pre-procedural and periprocedural re-rupture was a significant predictor of a poor patient outcome with an 83% incidence of TCD detected vasospasm and a poor outcome (mGOS 5/5) in 7/14 (50%) patients.

GOS may be impaired in patients who have no focal deficit—for example, neuropsychological disability—which may at least in part explain the lack of correlation with the presence of vasospasm. Elderly patients and those significantly damaged by their initial haemorrhage (whether or not they re-rupture) have a poor outcome that is not explained by the presence of vasospasm.

Although younger age was associated with a higher vasospasm risk, the outcome in the elderly with vasospasm was poorer. Intact vasoreactivity, efficient collateral flow, or improved cerebral reserve in young patients may all be factors operating to explain this phenomenon.

Vasospasm duration was not a predictor of outcome. It has been previously demonstrated that a significant rise in velocities may predict ischaemic neurological deficit. A sustained but modest increase in TCD velocity (shown in some of our patients) may be tolerated as collateralisation has time to become established and lessen the impact on overall cerebral perfusion. Chronic vessel wall changes after vasospasm may be responsible for persistent velocity abnormalities in the face of a clinically well patient.

The ISAT demonstrated a 22.6% relative, 6.9% absolute reduction in poor outcomes between endovascularly and surgically treated aneurysms. Our study suggests that this difference is not explained by differences in the incidence or severity of vasospasm, which is the same in the two treatment groups. Measures to more effectively monitor and reduce the clinical impact of vasospasm will improve patient outcomes even further.

CONCLUSION

Endovascular aneurysm treatment has no adverse impact on the occurrence of TCD detected vasospasm, on the incidence of ischaemic neurological deficit, or on overall patient outcome. The only factor that predicted the presence of vasospasm was young patient age. Factors correlating with poor patient outcomes were increasing age and admission WFNS grade. TCD correlates poorly with patient outcome.

Authors’ affiliations
A J P Goddard, P P J Raju, A Ghokkar, Neurosciences Department, Newcastle General Hospital, Westgate Road, Newcastle-upon-Tyne, NE4 6BE, UK
A J P Goddard, MRI Department, Imaging Centre, Queens Medical
Centre, Derby Road, Nottingham NG7 2UH, UK

Competing interests: none declared

REFERENCES
3 Adams HP Jr, Kassel NF, Torner JC, et al. Predicting outcome ischaemia after aeurysmal subarachnoid haemorrhage: influences of clinical condition, CT

www.jnnp.com
Value of serum prolactin in the management of syncope

S Ahmad and M W Beckett

J Neurol Neurosurg Psychiatry 2004 75: 872

Updated information and services can be found at:
http://jnnp.bmj.com/content/75/6/872

These include:

References
This article cites 1 articles, 1 of which you can access for free at:
http://jnnp.bmj.com/content/75/6/872#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/